CTI BioPharma Ratios and Metrics

Market cap in millions CAD. Fiscal year is January - December.

Millions CAD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2016 - 2020
Period Ending	Aug '25 Aug 7, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2016 - 2020
Market Capitalization	15	13	36	20	4	1	Upgrade
Market Cap Growth	-61.63%	-64.22%	75.93%	422.38%	298.80%	-40.00%	Upgrade
Enterprise Value	38	33	43	26	9	3	Upgrade
Last Close Price	0.04	0.03	0.09	0.10	0.04	0.01	Upgrade
PE Ratio	-	-	-	-	0.90	-	Upgrade
PS Ratio	0.90	0.77	3.03	1.69	0.98	0.32	Upgrade
PB Ratio	-4.14	-6.47	29.77	-3.28	-0.30	-0.05	Upgrade
P/TBV Ratio	-	-	29.77	-	-	-	Upgrade
P/FCF Ratio	-	-	-	-	-	1.60	Upgrade
P/OCF Ratio	-	-	22.31	3.81	-	1.55	Upgrade
EV/Sales Ratio	2.23	1.97	3.62	2.15	2.21	0.89	Upgrade
EV/EBITDA Ratio	22.69	14.24	-	12.11	2.63	-	Upgrade
EV/EBIT Ratio	-	-	-	33.23	3.04	-	Upgrade
EV/FCF Ratio	-3.37	-	-	-	-	4.49	Upgrade
Debt / Equity Ratio	-6.20	-9.98	7.94	-1.03	-0.56	-0.09	Upgrade
Debt / EBITDA Ratio	13.66	8.04	-	2.80	2.15	-	Upgrade
Debt / FCF Ratio	-	-	-	-	-	2.65	Upgrade
Asset Turnover	0.33	0.32	0.28	0.39	0.25	0.29	Upgrade
Inventory Turnover	17.42	19.57	17.42	22.02	21.81	18.01	Upgrade
Quick Ratio	0.10	0.11	0.15	0.10	0.19	0.25	Upgrade
Current Ratio	0.15	0.15	0.20	0.13	0.22	0.29	Upgrade
Return on Assets (ROA)	-3.05%	-1.91%	-5.86%	1.57%	11.39%	-69.33%	Upgrade
Return on Capital (ROIC)	-10.31%	-6.91%	-45.45%	-	-	-	Upgrade
Return on Capital Employed (ROCE)	-	-	-	4.70%	16.60%	-	Upgrade
Earnings Yield	-35.31%	-33.46%	-14.45%	-1.03%	111.66%	-1200.64%	Upgrade
FCF Yield	-73.75%	-70.63%	-38.58%	-10.58%	-160.37%	62.34%	Upgrade
Buyback Yield / Dilution	-8.45%	-18.98%	-110.66%	-72.97%	-50.69%	-17.98%	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.